Search

Your search keyword '"Sagae, Satoru"' showing total 208 results
Start Over Author "Sagae, Satoru" Search Limiters Academic (Peer-Reviewed) Journals
208 results on '"Sagae, Satoru"'

1. Management of Rare Uterine Malignant Tumors

Author

Amant, Frederic, Hensley, Martee, Pautier, Patricia, Friedlander, Michael, Sagae, Satoru, Fujiwara, Keiichi, Berton Rigaud, Dominique, Lorusso, Domenica, Ray-Coquard, Isabelle, and Mirza, Mansoor R., editor

Published
2020
Full Text
View/download PDF

2. Uterine serous carcinoma

Author

Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Y.L., Morice, Philippe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Nout, Remi A., Lorusso, Domenica, Vaughan, Michelle M., Bini, Marta, Takano, Masashi, Provencher, Diane, Indini, Alice, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Candido dos Reis, Francisco J., Lopez, Salvatore, Mariani, Andrea, Leitao, Mario M., Jr, Raspagliesi, Francesco, Panici, Pieluigi Benedetti, Di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Scambia, Giovanni, Pignata, Sandro, and Monk, Bradley J.

Published
2021
Full Text
View/download PDF

3. Gestational choriocarcinoma

Author

Bogani, Giorgio, primary, Ray-Coquard, Isabelle, additional, Mutch, David, additional, Vergote, Ignace, additional, Ramirez, Pedro T, additional, Prat, Jaime, additional, Concin, Nicole, additional, Ngoi, Natalie Yan Li, additional, Coleman, Robert L, additional, Enomoto, Takayuki, additional, Takehara, Kazuhiro, additional, Denys, Hannelore, additional, Lorusso, Domenica, additional, Takano, Masashi, additional, Sagae, Satoru, additional, Wimberger, Pauline, additional, Segev, Yakir, additional, Kim, Se Ik, additional, Kim, Jae-Weon, additional, Herrera, Fernanda, additional, Mariani, Andrea, additional, Brooks, Rebecca A, additional, Tan, David, additional, Paolini, Biagio, additional, Chiappa, Valentina, additional, Longo, Mariangela, additional, Raspagliesi, Francesco, additional, Benedetti Panici, Pierluigi, additional, Di Donato, Violante, additional, Caruso, Giuseppe, additional, Colombo, Nicoletta, additional, Pignata, Sandro, additional, Zannoni, Gianfranco, additional, Scambia, Giovanni, additional, and Monk, Bradley J, additional

Published
2023
Full Text
View/download PDF

4. Management of Rare Uterine Malignant Tumors

Author

Amant, Frederic, primary, Hensley, Martee, additional, Pautier, Patricia, additional, Friedlander, Michael, additional, Sagae, Satoru, additional, Fujiwara, Keiichi, additional, Berton Rigaud, Dominique, additional, Lorusso, Domenica, additional, and Ray-Coquard, Isabelle, additional

Published
2019
Full Text
View/download PDF

6. Endometrial carcinosarcoma

Author

Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Yan Li, Morice, Philippe, Caruso, Giuseppe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Lorusso, Domenica, Coleman, Robert, Vaughan, Michelle M, Takano, Masashi, Provencher, Diane Michele, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Kim, Jae-Weon, Candido Dos Reis, Francisco Jose, Ramirez, Pedro T, Mariani, Andrea, Leitao, Mario, Makker, Vicky, Abu-Rustum, Nadeem R, Vergote, Ignace, Zannoni, Gianfranco, Tan, David, Mccormack, Mary, Paolini, Biagio, Bini, Marta, Raspagliesi, Francesco, Benedetti Panici, Pierluigi, Di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, Monk, Bradley J, Scambia, Giovanni (ORCID:0000-0003-2758-1063), Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Yan Li, Morice, Philippe, Caruso, Giuseppe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Lorusso, Domenica, Coleman, Robert, Vaughan, Michelle M, Takano, Masashi, Provencher, Diane Michele, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Kim, Jae-Weon, Candido Dos Reis, Francisco Jose, Ramirez, Pedro T, Mariani, Andrea, Leitao, Mario, Makker, Vicky, Abu-Rustum, Nadeem R, Vergote, Ignace, Zannoni, Gianfranco, Tan, David, Mccormack, Mary, Paolini, Biagio, Bini, Marta, Raspagliesi, Francesco, Benedetti Panici, Pierluigi, Di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, Monk, Bradley J, and Scambia, Giovanni (ORCID:0000-0003-2758-1063)

Abstract

Endometrial carcinosarcoma is a rare and aggressive high-grade endometrial carcinoma with secondary sarcomatous trans-differentiation (conversion theory). The clinical presentation and diagnostic work-up roughly align with those of the more common endometrioid counterpart, although endometrial carcinosarcoma is more frequently diagnosed at an advanced stage. Endometrial carcinosarcoma is not a single entity but encompasses different histological subtypes, depending on the type of carcinomatous and sarcomatous elements. The majority of endometrial carcinosarcomas are characterized by p53 abnormalities. The proportion of POLE and microsatellite instablity-high (MSI-H) is directly related to the epithelial component, being approximately 25% and 3% in endometrioid and non-endometrioid components.The management of non-metastatic disease is based on a multimodal approach with optimal surgery followed by (concomitant or sequential) chemotherapy and radiotherapy, even for early stages. Palliative chemotherapy is recommended in the metastatic or recurrent setting, with carboplatin/paclitaxel doublet being the first-line regimen. Although the introduction of immunotherapy plus/minus a tyrosine kinase inhibitor shifted the paradigm of treatment of patients with recurrent endometrial cancer, patients with endometrial carcinosarcoma were excluded from most studies evaluating single-agent immunotherapy or the combination. However, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved the use of pembrolizumab and lenvatinib in endometrial cancer (all histotypes) after progression on chemotherapy and single-agent immunotherapy in MSI-H cancers. In the era of precision medicine, emerging knowledge on molecular endometrial carcinosarcoma is opening new promising therapeutic options for more personalized treatment. The present review outlines state-of-the-art knowledge and future directions for patients with endometrial carcinosarcoma.

Published
2023

7. Endometrial carcinosarcoma

Author

Bogani, G, Ray-Coquard, I, Concin, N, Ngoi, N, Morice, P, Caruso, G, Enomoto, T, Takehara, K, Denys, H, Lorusso, D, Coleman, R, Vaughan, M, Takano, M, Provencher, D, Sagae, S, Wimberger, P, Póka, R, Segev, Y, Kim, S, Kim, J, Candido Dos Reis, F, Ramirez, P, Mariani, A, Leitao, M, Makker, V, Abu-Rustum, N, Vergote, I, Zannoni, G, Tan, D, Mccormack, M, Paolini, B, Bini, M, Raspagliesi, F, Benedetti Panici, P, Di Donato, V, Muzii, L, Colombo, N, Pignata, S, Scambia, G, Monk, B, Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Yan Li, Morice, Philippe, Caruso, Giuseppe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Lorusso, Domenica, Coleman, Robert, Vaughan, Michelle M, Takano, Masashi, Provencher, Diane Michele, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Kim, Jae-Weon, Candido Dos Reis, Francisco Jose, Ramirez, Pedro T, Mariani, Andrea, Leitao, Mario, Makker, Vicky, Abu-Rustum, Nadeem R, Vergote, Ignace, Zannoni, Gianfranco, Tan, David, McCormack, Mary, Paolini, Biagio, Bini, Marta, Raspagliesi, Francesco, Benedetti Panici, Pierluigi, Di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, Monk, Bradley J, Bogani, G, Ray-Coquard, I, Concin, N, Ngoi, N, Morice, P, Caruso, G, Enomoto, T, Takehara, K, Denys, H, Lorusso, D, Coleman, R, Vaughan, M, Takano, M, Provencher, D, Sagae, S, Wimberger, P, Póka, R, Segev, Y, Kim, S, Kim, J, Candido Dos Reis, F, Ramirez, P, Mariani, A, Leitao, M, Makker, V, Abu-Rustum, N, Vergote, I, Zannoni, G, Tan, D, Mccormack, M, Paolini, B, Bini, M, Raspagliesi, F, Benedetti Panici, P, Di Donato, V, Muzii, L, Colombo, N, Pignata, S, Scambia, G, Monk, B, Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Yan Li, Morice, Philippe, Caruso, Giuseppe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Lorusso, Domenica, Coleman, Robert, Vaughan, Michelle M, Takano, Masashi, Provencher, Diane Michele, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Kim, Jae-Weon, Candido Dos Reis, Francisco Jose, Ramirez, Pedro T, Mariani, Andrea, Leitao, Mario, Makker, Vicky, Abu-Rustum, Nadeem R, Vergote, Ignace, Zannoni, Gianfranco, Tan, David, McCormack, Mary, Paolini, Biagio, Bini, Marta, Raspagliesi, Francesco, Benedetti Panici, Pierluigi, Di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, and Monk, Bradley J

Abstract

Endometrial carcinosarcoma is a rare and aggressive high-grade endometrial carcinoma with secondary sarcomatous trans-differentiation (conversion theory). The clinical presentation and diagnostic work-up roughly align with those of the more common endometrioid counterpart, although endometrial carcinosarcoma is more frequently diagnosed at an advanced stage. Endometrial carcinosarcoma is not a single entity but encompasses different histological subtypes, depending on the type of carcinomatous and sarcomatous elements. The majority of endometrial carcinosarcomas are characterized by p53 abnormalities. The proportion of POLE and microsatellite instablity-high (MSI-H) is directly related to the epithelial component, being approximately 25% and 3% in endometrioid and non-endometrioid components.The management of non-metastatic disease is based on a multimodal approach with optimal surgery followed by (concomitant or sequential) chemotherapy and radiotherapy, even for early stages. Palliative chemotherapy is recommended in the metastatic or recurrent setting, with carboplatin/paclitaxel doublet being the first-line regimen. Although the introduction of immunotherapy plus/minus a tyrosine kinase inhibitor shifted the paradigm of treatment of patients with recurrent endometrial cancer, patients with endometrial carcinosarcoma were excluded from most studies evaluating single-agent immunotherapy or the combination. However, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved the use of pembrolizumab and lenvatinib in endometrial cancer (all histotypes) after progression on chemotherapy and single-agent immunotherapy in MSI-H cancers. In the era of precision medicine, emerging knowledge on molecular endometrial carcinosarcoma is opening new promising therapeutic options for more personalized treatment. The present review outlines state-of-the-art knowledge and future directions for patients with endometrial carcinosarcoma.

Published
2023

9. Endometrial carcinosarcoma

Author

Bogani, Giorgio, primary, Ray-Coquard, Isabelle, additional, Concin, Nicole, additional, Ngoi, Natalie Yan Li, additional, Morice, Philippe, additional, Caruso, Giuseppe, additional, Enomoto, Takayuki, additional, Takehara, Kazuhiro, additional, Denys, Hannelore, additional, Lorusso, Domenica, additional, Coleman, Robert, additional, Vaughan, Michelle M, additional, Takano, Masashi, additional, Provencher, Diane Michele, additional, Sagae, Satoru, additional, Wimberger, Pauline, additional, Póka, Robert, additional, Segev, Yakir, additional, Kim, Se Ik, additional, Kim, Jae-Weon, additional, Candido dos Reis, Francisco Jose, additional, Ramirez, Pedro T, additional, Mariani, Andrea, additional, Leitao, Mario, additional, Makker, Vicky, additional, Abu-Rustum, Nadeem R, additional, Vergote, Ignace, additional, Zannoni, Gianfranco, additional, Tan, David, additional, McCormack, Mary, additional, Paolini, Biagio, additional, Bini, Marta, additional, Raspagliesi, Francesco, additional, Benedetti Panici, Pierluigi, additional, Di Donato, Violante, additional, Muzii, Ludovico, additional, Colombo, Nicoletta, additional, Pignata, Sandro, additional, Scambia, Giovanni, additional, and Monk, Bradley J, additional

Published
2022
Full Text
View/download PDF

11. Clear cell carcinoma of the endometrium

Author

Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Y L, Morice, Philippe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Lorusso, Domenica, Coleman, Robert, Vaughan, Michelle M, Takano, Masashi, Provencher, Diane, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Kim, Jae-Weon, Candido Dos Reis, Francisco J, Mariani, Andrea, Leitao, Mario M, Makker, Viky, Rustum, Nadeem Abu, Vergote, Ignace, Zannoni, Gian Franco, Tan, David S P, Mccormack, Mary, Bini, Marta, Lopez, Salvatore, Raspagliesi, Francesco, Panici, Pierluigi Benedetti, di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Scambia, Giovanni, Pignata, Sandro, Monk, Bradley J, Zannoni, Gian Franco (ORCID:0000-0003-1809-129X), Scambia, Giovanni (ORCID:0000-0003-2758-1063), Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Y L, Morice, Philippe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Lorusso, Domenica, Coleman, Robert, Vaughan, Michelle M, Takano, Masashi, Provencher, Diane, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Kim, Jae-Weon, Candido Dos Reis, Francisco J, Mariani, Andrea, Leitao, Mario M, Makker, Viky, Rustum, Nadeem Abu, Vergote, Ignace, Zannoni, Gian Franco, Tan, David S P, Mccormack, Mary, Bini, Marta, Lopez, Salvatore, Raspagliesi, Francesco, Panici, Pierluigi Benedetti, di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Scambia, Giovanni, Pignata, Sandro, Monk, Bradley J, Zannoni, Gian Franco (ORCID:0000-0003-1809-129X), and Scambia, Giovanni (ORCID:0000-0003-2758-1063)

Abstract

Clear cell endometrial carcinoma represents an uncommon and poorly understood entity. Data from molecular/genomic profiling highlighted the importance of various signatures in assessing the prognosis of endometrial cancer according to four classes of risk (POLE mutated, MMRd, NSMP, and p53 abnormal). Unfortunately, data specific to clear cell histological subtype endometrial cancer are lacking. More recently, data has emerged to suggest that most of the patients (more than 80%) with clear cell endometrial carcinoma are characterized by p53 abnormality or NSMP type. This classification has important therapeutic implications. Although it is an uncommon entity, clear cell endometrial cancer patients with POLE mutation seem characterized by a good prognosis. Chemotherapy is effective in patients with NSMP (especially in stage III and IV) and patients with p53 abnormal disease (all stages). While, preliminary data suggested that patients with MMRd are less likely to benefit from chemotherapy. The latter group appears to benefit much more from immune checkpoint inhibitors: recent data from clinical trials on pembrolizumab plus lenvatinib and nivolumab plus cabozantinib supported that immunotherapy plus tyrosine kinase inhibitors (TKI) would be the most appropriate treatment for recurrent non-endometrioid endometrial cancer (including clear cell carcinoma) after the failure of platinum-based chemotherapy. Moreover, ongoing clinical trials testing the anti-tumor activity of innovative products will clarify the better strategies for advanced/recurrent clear cell endometrial carcinoma. Further prospective evidence is urgently needed to better characterize clear cell endometrial carcinoma. (C) 2022 Elsevier Inc. All rights reserved.

Published
2022

12. Clear cell carcinoma of the endometrium

Author

Bogani, Giorgio, primary, Ray-Coquard, Isabelle, additional, Concin, Nicole, additional, Ngoi, Natalie Y.L., additional, Morice, Philippe, additional, Enomoto, Takayuki, additional, Takehara, Kazuhiro, additional, Denys, Hannelore, additional, Lorusso, Domenica, additional, Coleman, Robert, additional, Vaughan, Michelle M., additional, Takano, Masashi, additional, Provencher, Diane, additional, Sagae, Satoru, additional, Wimberger, Pauline, additional, Póka, Robert, additional, Segev, Yakir, additional, Kim, Se Ik, additional, Kim, Jae-Weon, additional, Candido dos Reis, Francisco J., additional, Mariani, Andrea, additional, Leitao, Mario M., additional, Makker, Viky, additional, Rustum, Nadeem Abu, additional, Vergote, Ignace, additional, Zannoni, Gian Franco, additional, Tan, David S.P., additional, McCormack, Mary, additional, Bini, Marta, additional, Lopez, Salvatore, additional, Raspagliesi, Francesco, additional, Panici, Pierluigi Benedetti, additional, di Donato, Violante, additional, Muzii, Ludovico, additional, Colombo, Nicoletta, additional, Scambia, Giovanni, additional, Pignata, Sandro, additional, and Monk, Bradley J., additional

Published
2022
Full Text
View/download PDF

13. Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition

Author

Nagase, Satoru, Katabuchi, Hidetaka, Hiura, Masamichi, Sakuragi, Noriaki, Aoki, Yoichi, Kigawa, Junzo, Saito, Tsuyoshi, Hachisuga, Toru, Ito, Kiyoshi, Uno, Takashi, Katsumata, Noriyuki, Komiyama, Shinichi, Susumu, Nobuyuki, Emoto, Makoto, Kobayashi, Hiroaki, Metoki, Hirohito, Konishi, Ikuo, Ochiai, Kazunori, Mikami, Mikio, Sugiyama, Toru, Mukai, Makio, Sagae, Satoru, Hoshiai, Hiroshi, Aoki, Daisuke, Ohmichi, Masahide, Yoshikawa, Hiroyuki, Iwasaka, Tsuyoshi, Udagawa, Yasuhiro, and Yaegashi, Nobuo

Published
2010
Full Text
View/download PDF

27. Liquid Nitrogen cryotherapy (N2Cryo) for Cervical intraepithelial neoplasia (CIN)

Author

Sagae, Satoru

Abstract

Purpose: In general patients with ASC-US/LSIL cytology will be followed periodically with 3 or 6 months interval. We performed liquid nitrogen cryotherapy (N2Cryo) of less than thirty second duration for the purpose of clearance of abnormal cytology and persistent HPV infection.Material and Method: Between April 2015 to September 2019, retrospectively we analyzed patients with abnormal cytology of ASC-US/LSIL into the groups: A group of 47 cases with just follow-up without any treatment, B group of 45 cases with N2Cryo according to colposcopic and/or cytological abnormality and HPV infection. Furthermore, 31 patients with HSIL undergone N2Cryo were also compared to the effectiveness of clearance of abnormal cytology and HPV infection. Patients performed N2Cryo three times every four weeks with written informed consent. Results: Among 47 patients with ASC-US/LSIL followed by no treatment, 4 cases recovered spontaneously with normal cytology (NILM) and HPV negative (complete regression: CR), 14 cases with partial regression (PR) (CR+PR Regression Rate (RR): 38.3%) including NILM or HPV negative, 10 cases with persistence, a case with progressed to HSIL. However, 15 cases were missed with no visit during follow-up. Among 45 patients with ASC-US/LSIL treated by N2Cryo, 14 cases showed CR, 14 cases showed PR, with RR: 62.2%, including 11 cases with persistence and progression.Furthermore, 31 cases with HSIL treated by N2Cryo, 9 cases showed CR, 12 cases showed PR with RR: 67.7%, and 6 cases with persistence.Conclusion: Liquid nitrogen cryotherapy (N2Cryo) might be useful for the CIN regression, especially with avoidance of cone biopsy for cases with HSIL.

Published
2017

28. Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future

Author

Sagae, Satoru, primary, Monk, Bradley J., additional, Pujade-Lauraine, Eric, additional, Gaffney, David K., additional, Narayan, Kailash, additional, Ryu, Sang Young, additional, McCormack, Mary, additional, Plante, Marie, additional, Casado, Antonio, additional, Reuss, Alexander, additional, Chávez-Blanco, Adriana, additional, Kitchener, Henry, additional, Nam, Byung-Ho, additional, Jhingran, Anuja, additional, Temkin, Sarah, additional, Mileshkin, Linda, additional, Berns, Els, additional, Scholl, Suzy, additional, Doll, Corinne, additional, Abu-Rustum, Nadeem R., additional, Lecuru, Fabrice, additional, and Small, William, additional

Published
2016
Full Text
View/download PDF

29. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine Serous Carcinoma

Author

Sagae, Satoru, primary, Susumu, Nobuyuki, additional, Viswanathan, Akila N., additional, Aoki, Daisuke, additional, Backes, Floor J., additional, Provencher, Diane M., additional, Vaughan, Michelle, additional, Creutzberg, Carien L., additional, Kurzeder, Christian, additional, Kristensen, Gunnar, additional, Lee, Chulmin, additional, Kurtz, Jean-Emmanuel, additional, Glasspool, Rosalind M., additional, and Small, William, additional

Published
2014
Full Text
View/download PDF

30. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

Author

Rustin, Gordon John Sampson, primary, Vergote, Ignace, additional, Eisenhauer, Elizabeth, additional, Pujade-Lauraine, Eric, additional, Quinn, Michael, additional, Thigpen, Tate, additional, du Bois, Andreas, additional, Kristensen, Gunnar, additional, Jakobsen, Anders, additional, Sagae, Satoru, additional, Greven, Kathryn, additional, Parmar, Mahesh, additional, Friedlander, Michael, additional, Cervantes, Andres, additional, and Vermorken, Jan, additional

Published
2011
Full Text
View/download PDF

32. The Impact of Complete Surgical Staging Upon Survival in Early-Stage Ovarian Clear Cell Carcinoma

Author

Takano, Masashi, primary, Sugiyama, Toru, additional, Yaegashi, Nobuo, additional, Suzuki, Mitsuaki, additional, Tsuda, Hiroshi, additional, Sagae, Satoru, additional, Udagawa, Yasuhiro, additional, Kuzuya, Kazuo, additional, Kigawa, Junzo, additional, Takeuchi, Satoshi, additional, Tsuda, Hitoshi, additional, Moriya, Takuya, additional, and Kikuchi, Yoshihiro, additional

Published
2009
Full Text
View/download PDF

36. Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary

Author

Takano, Masashi, primary, Kikuchi, Yoshihiro, additional, Yaegashi, Nobuo, additional, Suzuki, Mitsuaki, additional, Tsuda, Hiroshi, additional, Sagae, Satoru, additional, Udagawa, Yasuhiro, additional, Kuzuya, Kazuo, additional, Kigawa, Junzo, additional, Takeuchi, Satoshi, additional, Tsuda, Hitoshi, additional, Moriya, Takuya, additional, and Sugiyama, Toru, additional

Published
2006
Full Text
View/download PDF

37. Epigenetic Inactivation ofTMS1/ASCin Ovarian Cancer

Author

Terasawa, Katsuhiko, primary, Sagae, Satoru, additional, Toyota, Minoru, additional, Tsukada, Kuniko, additional, Ogi, Kazuhiro, additional, Satoh, Ayumi, additional, Mita, Hiroaki, additional, Imai, Kohzoh, additional, Tokino, Takashi, additional, and Kudo, Ryuichi, additional

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results